吉华集团：子公司获得利斯的明透皮贴剂药品注册证书

Core Viewpoint - Jihua Group's subsidiary Jiangsu Kangbeide Pharmaceutical Co., Ltd. has received approval from the National Medical Products Administration for two registrations of Lisdexamfetamine transdermal patches, indicating a significant advancement in the company's product portfolio and potential market opportunities [1] Group 1 - The approved drug is Lisdexamfetamine transdermal patch, with active ingredient Lisdexamfetamine [1] - The specifications for the patches are 4.6mg/24 hours and 9.5mg/24 hours, classified as chemical drug category 4 [1] - The registration certificates have effective dates until June 9, 2030, with specific approval numbers provided [1] Group 2 - The total research and development investment for the Lisdexamfetamine transdermal patch project amounts to approximately 20 million RMB [1]